PMID- 23320107
OWN - NLM
STAT- MEDLINE
DCOM- 20130815
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 1
DP  - 2013
TI  - Association of increased frequencies of HLA-DPB1*05:01 with the presence of 
      anti-Ro/SS-A and anti-La/SS-B antibodies in Japanese rheumatoid arthritis and 
      systemic lupus erythematosus patients.
PG  - e53910
LID - 10.1371/journal.pone.0053910 [doi]
LID - e53910
AB  - INTRODUCTION: Autoantibodies to ribonucleoprotein are associated with a variety 
      of autoimmune diseases, including rheumatoid arthritis (RA). Many studies on 
      associations between human leukocyte antigen (HLA) alleles and RA have been 
      reported, but few have been validated in RA subpopulations with anti-La/SS-B or 
      anti-Ro/SS-A antibodies. Here, we investigated associations of HLA class II 
      alleles with the presence of anti-Ro/SS-A or anti-La/SS-B antibodies in RA. 
      METHODS: An association study was conducted for HLA-DRB1, DQB1, and DPB1 in 
      Japanese RA and systemic lupus erythematosus (SLE) patients that were positive or 
      negative for anti-Ro/SS-A and/or anti-La/SS-B antibodies. RESULTS: An increased 
      prevalence of certain class II alleles was associated with the presence of 
      anti-Ro/SS-A antibodies as follows: DRB1*08:03 (Pc = 3.79x10(-5), odds ratio [OR] 
      3.06, 95% confidence interval [CI] 1.98-4.73), DQB1*06:01 (Pc = 0.0106, OR 1.70, 
      95%CI 1.26-2.31), and DPB1*05:01 (Pc = 0.0040, OR 1.55, 95%CI 1.23-1.96). On the 
      other hand, DRB1*15:01 (Pc = 0.0470, OR 3.14, 95%CI 1.63-6.05), DQB1*06:02 
      (Pc = 0.0252, OR 3.14, 95%CI 1.63-6.05), and DPB1*05:01 (Pc = 0.0069, OR 2.27, 
      95% CI 1.44-3.57) were associated with anti-La/SS-B antibodies. The DPB1*05:01 
      allele was associated with anti-Ro/SS-A (Pc = 0.0408, OR 1.69, 95% CI 1.19-2.41) 
      and anti-La/SS-B antibodies (Pc = 2.48x10(-5), OR 3.31, 95%CI 2.02-5.43) in SLE 
      patients. CONCLUSION: HLA-DPB1*05:01 was the only allele associated with the 
      presence of both anti-Ro/SS-A and anti-La/SS-B antibodies in Japanese RA and SLE 
      patients.
FAU - Furukawa, Hiroshi
AU  - Furukawa H
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sagamihara, Japan. 
      h-furukawa@sagamihara-hosp.gr.jp
FAU - Oka, Shomi
AU  - Oka S
FAU - Shimada, Kota
AU  - Shimada K
FAU - Sugii, Shoji
AU  - Sugii S
FAU - Hashimoto, Atsushi
AU  - Hashimoto A
FAU - Komiya, Akiko
AU  - Komiya A
FAU - Fukui, Naoshi
AU  - Fukui N
FAU - Nagai, Tatsuo
AU  - Nagai T
FAU - Hirohata, Shunsei
AU  - Hirohata S
FAU - Setoguchi, Keigo
AU  - Setoguchi K
FAU - Okamoto, Akira
AU  - Okamoto A
FAU - Chiba, Noriyuki
AU  - Chiba N
FAU - Suematsu, Eiichi
AU  - Suematsu E
FAU - Miyashita, Taiichiro
AU  - Miyashita T
FAU - Migita, Kiyoshi
AU  - Migita K
FAU - Suda, Akiko
AU  - Suda A
FAU - Nagaoka, Shouhei
AU  - Nagaoka S
FAU - Tsuchiya, Naoyuki
AU  - Tsuchiya N
FAU - Tohma, Shigeto
AU  - Tohma S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130108
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1 antigen)
RN  - 0 (HLA-DPB1*05:01 antigen)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQbeta antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (SS-A antibodies)
RN  - 0 (SS-B antibodies)
SB  - IM
MH  - Aged
MH  - Antibodies, Antinuclear/*blood
MH  - Arthritis, Rheumatoid/*genetics/*immunology
MH  - Asian People/genetics
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency
MH  - Genes, MHC Class II
MH  - Genetic Association Studies
MH  - HLA-DP beta-Chains/*genetics
MH  - HLA-DQ beta-Chains/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - Humans
MH  - Japan
MH  - Lupus Erythematosus, Systemic/*genetics/*immunology
MH  - Male
MH  - Middle Aged
MH  - Sjogren's Syndrome/genetics/immunology
PMC - PMC3540046
COIS- Competing Interests: HF has the following conflicts. The following funders are 
      supported in whole or in part by the indicated pharmaceutical companies. The 
      Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the 
      Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical 
      Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical 
      Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa 
      Securities Group Inc. ST was supported by research grants from nine 
      pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai 
      Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, 
      Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company 
      Limited, and Teijin Pharma Limited. NT is supported by the Takeda Science 
      Foundation, which is supported by an endowment from the Takeda Pharmaceutical 
      Company. This does not alter the authors' adherence to all the PLOS ONE policies 
      on sharing data and materials. The other authors declare no financial or 
      commercial conflicts of interest.
EDAT- 2013/01/16 06:00
MHDA- 2013/08/16 06:00
PMCR- 2013/01/08
CRDT- 2013/01/16 06:00
PHST- 2012/08/16 00:00 [received]
PHST- 2012/12/04 00:00 [accepted]
PHST- 2013/01/16 06:00 [entrez]
PHST- 2013/01/16 06:00 [pubmed]
PHST- 2013/08/16 06:00 [medline]
PHST- 2013/01/08 00:00 [pmc-release]
AID - PONE-D-12-24472 [pii]
AID - 10.1371/journal.pone.0053910 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(1):e53910. doi: 10.1371/journal.pone.0053910. Epub 2013 Jan 8.